Terumo Neuro has today announced the commercial availability of the Sofia Flow 88 neurovascular aspiration catheter in Europe, the Middle East and Africa (EMEA), expanding the company’s stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control, the company claims.
This launch builds on the “proven clinical performance and global legacy” of the Sofia catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade, according to Terumo Neuro. A press release goes on to note that the company is showcasing its complete line of stroke solutions at this week’s LINNC Paris meeting (2–4 June, Paris, France).
Leveraging more than 10 years of neurovascular catheter innovation, physician partnerships and proven clinical performance, the Sofia 88 neurovascular aspiration catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements intended to provide the following benefits: reliable trackability, proximal stability, an atraumatic design, and ability to engage clots and aspirate confidently.
“As we introduce the Sofia Flow 88 neurovascular aspiration catheter, we are building on a decade of performance that physicians around the world have come to trust,” said Carsten Schroeder, president and chief executive officer (CEO) of Terumo Neuro. “This launch is a reflection of our continued investment in neurovascular innovation, made possible through direct collaboration with physicians, and our strong R&D [research and development] and manufacturing capabilities. Together, we are delivering meaningful advancements in stroke care designed to improve outcomes for patients worldwide.”
The Sofia 88 neurovascular aspiration catheter is compatible with the Sofia Plus 6Fr aspiration catheter and supports integration into existing aspiration strategies, the company further claims. Clinical evidence from the SOFAST registry and also the SESAME trial—evaluating the Sofia Plus 6Fr as a first-line approach—demonstrated strong results regarding speed, efficacy, and safety, and overall clinical outcomes.
